Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Share on facebook
Share on twitter
Share on linkedin

BioNJ COVID-19 Rapid Fire Research Showcase

BioAegis has been selected as a featured company in the upcoming BioNJ COVID-19 Rapid Fire Research Showcase

Our Chief Executive Officer and Co-founder, Dr. Susan Levinson, will present our goundbreaking recombinant human plasma gelsolin (rhu-pGSN) therapy.

WHEN:    Friday, June 5, 2020, 9:00 a.m. – 10:00 a.m.